NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ: NAMS · HEALTHCARE · BIOTECHNOLOGY
$28.43
-1.01% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
145.26x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$17 – $42
Volume
0.9M
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | $139.87M | $67.99M | $478.50M | $347.10M | $864.62M |
| Cash & equivalents | — | — | — | — | — |
| Current assets | $1.87M | $66.96M | $477.98M | $346.79M | $863.41M |
| Total liabilities | $12.41M | $11.36M | $48.43M | $58.70M | $107.12M |
| Current liabilities | $236521.00 | $11.24M | $36.06M | $49.90M | $106.92M |
| Long-term debt | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — |
| Retained earnings | $41453.00 | $-39.44M | $-140.04M | $-316.97M | $-558.57M |
| Accounts receivable | — | $4.86M | $2.07M | $1.88M | $21.30M |
| Inventory | — | $-735.00 | $21500.00 | $-1.71M | — |
| Goodwill | — | — | $233104.00 | — | — |